Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor
With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared ...
Hims & Hers: Brace For Impact As It Faces A Possible 18% Revenue Hit
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Hims & Hers shares plunge as looming curbs on drug compounding cloud forecast
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
HIMS Earnings: Shares Sink despite Smashing Guidance Estimates
Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...
Hims & Hers offers upbeat forecast, but stock slides after hours
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Modern Healthcare2d
Hims & Hers pivots as semaglutide shortage ends
Hims & Hers faces new headwinds in its weight management segment with the Food and Drug Administration ending the shortage of ...
Hims & Hers (HIMS) Sees 69% Revenue Increase Despite GLP-1 Uncertainties
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
KIVI-TV1d
Hims and Hers likely to stop selling cheaper versions of GLP-1 medications
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
Why Hims & Hers Health, Inc. (HIMS) Went Down on Tuesday
We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...